Stock listing
B3:BIOM3 Biomm SA Ações
Home listing (B3) of Biomm SA
Follow Biomm SA into a list and get an email when it puts out news.
Share price · BMFBOVESPA:BIOM3
5.33 BRL -0.35 (-6.2%)
Close on Nov 19, 2026
- Day range
- 5.33 – 5.82 BRLNov 19, 2026
- Volume
- 264,100 sharesNov 19, 2026
- Market cap
- 729.4M BRLAt the close on Nov 19, 2026 · price × 136.9M shares outstanding
- 52-week range
- 4.81 – 9.75 BRLLowest and highest trades, Nov 21, 2025 – Nov 19, 2026
- Traded on an average day
- 390,948 BRLMedian day 40,300 shares · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| B3:BIOM3 · Home | 5.33 BRL | -0.35 (-6.2%) | 264,100 | 5.80 | 5.82 | 5.33 | 5.68 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · BMFBOVESPA:BIOM3 · BRL, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 5.33 | -0.35 | -6.2% | 5.80 | 5.82 | 5.33 | 264,100 | |
| 5.68 | +0.13 | +2.3% | 5.40 | 5.89 | 5.40 | 211,000 | |
| 5.55 | -0.45 | -7.5% | 5.72 | 5.87 | 5.55 | 140,300 | |
| 6.00 | +0.54 | +9.9% | 5.54 | 6.00 | 5.54 | 15,200 | |
| 5.46 | -0.38 | -6.5% | 5.84 | 6.00 | 5.46 | 34,600 | |
| 5.84 | +0.62 | +11.9% | 5.42 | 5.90 | 5.26 | 80,500 | |
| 5.22 | -0.64 | -10.9% | 5.87 | 5.87 | 4.81 | 233,700 | |
| 5.86 | -0.07 | -1.2% | 5.81 | 5.87 | 5.80 | 11,800 | |
| 5.93 | +0.43 | +7.8% | 5.84 | 5.94 | 5.61 | 86,400 | |
| 5.50 | -0.83 | -13.1% | 6.29 | 6.50 | 5.50 | 123,000 | |
| 6.33 | +1.28 | +25.3% | 5.32 | 6.33 | 5.14 | 119,300 | |
| 5.05 | -0.25 | -4.7% | 5.29 | 5.45 | 5.00 | 19,800 | |
| 5.30 | -0.05 | -0.9% | 5.41 | 5.48 | 5.30 | 17,500 | |
| 5.35 | +0.02 | +0.4% | 5.55 | 5.55 | 5.35 | 37,200 | |
| 5.33 | -0.19 | -3.4% | 5.61 | 5.61 | 5.32 | 41,300 | |
| 5.52 | +0.07 | +1.3% | 5.75 | 5.89 | 5.50 | 50,000 | |
| 5.45 | -0.45 | -7.6% | 5.70 | 5.80 | 5.41 | 140,400 | |
| 5.90 | 0.00 | 0.0% | 6.00 | 6.10 | 5.90 | 156,900 | |
| 5.90 | -0.06 | -1.0% | 6.00 | 6.02 | 5.90 | 40,300 | |
| 5.96 | -0.37 | -5.8% | 6.13 | 6.20 | 5.96 | 26,600 | |
| 6.33 | +0.35 | +5.9% | 6.00 | 6.33 | 5.94 | 25,700 | |
| 5.98 | +0.08 | +1.4% | 5.99 | 6.18 | 5.94 | 47,600 | |
| 5.90 | -0.20 | -3.3% | 6.09 | 6.14 | 5.90 | 96,000 | |
| 6.10 | -0.21 | -3.3% | 6.23 | 6.23 | 5.90 | 120,800 | |
| 6.31 | -0.30 | -4.5% | 6.53 | 6.63 | 6.31 | 79,100 | |
| 6.61 | -0.73 | -9.9% | 7.15 | 7.33 | 6.61 | 65,300 | |
| 7.34 | +0.25 | +3.5% | 7.15 | 7.60 | 7.14 | 134,800 | |
| 7.09 | +0.19 | +2.8% | 6.94 | 7.10 | 6.90 | 71,100 | |
| 6.90 | +0.04 | +0.6% | 6.85 | 7.10 | 6.63 | 184,700 | |
| 6.86 | +0.42 | +6.5% | 6.43 | 6.86 | 6.43 | 119,600 | |
| 6.44 | -0.01 | -0.2% | 6.56 | 7.40 | 6.40 | 88,100 | |
| 6.45 | +0.39 | +6.4% | 6.12 | 6.45 | 5.96 | 57,300 | |
| 6.06 | -0.04 | -0.7% | 6.11 | 6.15 | 5.86 | 46,800 | |
| 6.10 | +0.22 | +3.7% | 5.90 | 6.10 | 5.81 | 55,200 | |
| 5.88 | -0.10 | -1.7% | 6.04 | 6.29 | 5.77 | 39,600 | |
| 5.98 | -0.15 | -2.4% | 5.94 | 6.29 | 5.71 | 127,700 | |
| 6.13 | +0.13 | +2.2% | 5.91 | 6.20 | 5.91 | 21,500 | |
| 6.00 | -0.26 | -4.2% | 6.29 | 6.29 | 6.00 | 27,200 | |
| 6.26 | -0.15 | -2.3% | 6.42 | 6.44 | 6.26 | 5,200 | |
| 6.41 | -0.06 | -0.9% | 6.46 | 6.47 | 6.38 | 2,900 | |
| 6.47 | +0.21 | +3.4% | 6.29 | 6.47 | 6.29 | 11,800 | |
| 6.26 | 0.00 | 0.0% | 6.35 | 6.36 | 6.26 | 37,100 | |
| 6.26 | -0.35 | -5.3% | 6.56 | 6.56 | 6.26 | 195,700 | |
| 6.61 | +0.11 | +1.7% | 6.51 | 6.73 | 6.43 | 22,500 | |
| 6.50 | -0.03 | -0.5% | 6.55 | 6.69 | 6.48 | 20,600 | |
| 6.53 | -0.17 | -2.5% | 6.70 | 6.70 | 6.52 | 1,600 | |
| 6.70 | +0.12 | +1.8% | 6.53 | 6.78 | 6.53 | 51,100 | |
| 6.58 | +0.02 | +0.3% | 6.53 | 6.74 | 6.47 | 89,500 | |
| 6.56 | -0.23 | -3.4% | 6.63 | 6.77 | 6.53 | 24,200 | |
| 6.79 | +0.16 | +2.4% | 6.54 | 6.80 | 6.54 | 9,800 | |
| 6.63 | +0.21 | +3.3% | 6.37 | 6.63 | 6.37 | 22,300 | |
| 6.42 | -0.03 | -0.5% | 6.46 | 6.46 | 6.41 | 3,300 | |
| 6.45 | +0.28 | +4.5% | 6.34 | 6.45 | 6.29 | 31,000 | |
| 6.17 | -0.10 | -1.6% | 6.49 | 6.49 | 6.17 | 5,600 | |
| 6.27 | -0.07 | -1.1% | 6.37 | 6.50 | 6.20 | 10,800 | |
| 6.34 | -0.02 | -0.3% | 6.38 | 6.45 | 6.11 | 22,300 | |
| 6.36 | -0.08 | -1.2% | 6.64 | 6.64 | 6.36 | 10,200 | |
| 6.44 | -0.33 | -4.9% | 6.63 | 6.63 | 6.44 | 11,700 | |
| 6.77 | +0.17 | +2.6% | 6.79 | 6.79 | 6.32 | 91,000 | |
| 6.60 | 0.00 | 0.0% | 6.50 | 6.78 | 6.27 | 70,500 | |
| 6.60 | +0.48 | +7.8% | 6.16 | 6.60 | 6.16 | 26,200 | |
| 6.12 | -0.28 | -4.4% | 6.41 | 6.42 | 6.03 | 17,300 | |
| 6.40 | -0.10 | -1.5% | 6.48 | 6.50 | 6.30 | 3,200 |
- Ticker
- B3:BIOM3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- B3
- Currency
- BRL
What changed lately
Latest news release · Nov 24, 2025
Brazil's Biomm CEO Heraldo Marchezini resigns; Guilherme Maradei to take the role
Latest news
Brazil's Biomm CEO Heraldo Marchezini resigns; Guilherme Maradei to take the role
Nov 24, 2025
Closed 7.16 (+0.3%) on Nov 25, 2025
Biomm SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 2 in all · newest Nov 24, 2025 · oldest 2025
Where Biomm SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| B3:BIOM3 · Home listing · This page | B3 | Brazil | BRL |
| B3:BIOM3F | B3 | Brazil | BRL |
Valuation
EV/sales 2.1× against a median of 26.7×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- 812.0M BRL
- P/E
- 18.4×
- EV/sales
- 2.1×
- EV/EBITDA
- 12.3×
- Price/book
- 2.2×
- Gross margin
- 35.4%
- Operating margin
- 13.8%
- Net margin
- 10.3%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Biomm SA · BMFBOVESPA:BIOM3 | US$123.5M | US$137.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.39M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.24M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| Median of the others | US$123.8M | US$81.81M | 26.7× | 3.9× | −180.6% | 0.1× | 1.08 |
Team and board
Officers
| Officer | Role |
|---|---|
| Guilherme Maradei | Chief Executive Officer |
| Marclo Sáfadi Alvares | Chief Financial and Investor Relations Officer |
| Alexandre Bernardes Gonçalves | Commercial Director |
| André Capistrano Emrich | Member of the Executive Committee |
| Anna Emilia Sousa Leite Gaetani | Manager |
| Davi Khattar | Manager |
| Francisco Carlos Marques de Freitas | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Cláudio Luiz Lottenberg | Chairman of the Board |
| André Capistrano Emrich | Member of the Executive Committee |
| Walfrido Silvino dos Mares Guia Neto | Vice Chairman of the Board |
Financials
Annual, in BRL
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.3M | 142.9M | 118.2M | 105.0M | 107.1M | 58.7M | 8.94M | 1.57M | 103.0K | 0 |
| Cost of revenue | 187.5M | 125.0M | 94.9M | 89.0M | 80.2M | 44.7M | 8.42M | 1.32M | 67.0K | 420.0K |
| Gross profit | 81.8M | 17.9M | 23.3M | 16.0M | 26.9M | 13.9M | 521.0K | 245.0K | 36.0K | -420.0K |
| Research and development | 4.46M | 4.38M | ||||||||
| Selling, general and administrative | 48.2M | 49.7M | 48.1M | 50.2M | 47.3M | 35.4M | 32.2M | 32.6M | 31.2M | 27.4M |
| Operating income | 4.83M | -81.2M | -72.5M | -86.2M | -65.6M | -55.4M | -52.6M | -36.7M | -35.4M | -30.6M |
| Depreciation and amortization | 8.57M | 11.9M | 11.5M | 12.3M | 11.6M | 10.5M | 4.62M | 1.74M | 495.0K | 420.0K |
| EBITDA | 13.4M | -69.3M | -61.0M | -74.0M | -54.0M | -44.9M | -48.0M | -34.9M | -34.9M | -30.2M |
| Interest expense | 13.1M | 12.9M | 15.0M | 16.8M | 17.3M | 14.1M | 12.6M | 19.3M | 16.2M | 6.00M |
| Income before tax | -6.95M | -76.6M | -80.8M | -93.2M | -79.8M | -70.7M | -55.8M | -42.5M | -41.0M | -50.0M |
| Income tax | -261.0K | 644.0K | 340.0K | -630.0K | 475.0K | 63.0K | 38.0K | 33.0K | -2.90M | -4.41M |
| Net income | -6.69M | -77.2M | -81.1M | -92.6M | -80.3M | -70.8M | -55.8M | -42.6M | -38.1M | -45.6M |
| Earnings per share, basic | -0.05 | -0.63 | -0.98 | -1.26 | -1.15 | -1.12 | -1.11 | -0.97 | -1.10 | -1.42 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 22.3M | 77.6M | 26.0M | 75.9M | 31.4M | 57.4M | 30.1M | 21.0M | 8.63M | 7.83M |
| Short-term investments | 20.9M | 65.8M | 27.7M | 28.6M | 23.8M | 84.7M | 74.6M | 67.0M | 32.5M | 30.7M |
| Receivables | 124.5M | 22.9M | 26.4M | 25.5M | 27.6M | 20.5M | 4.96M | 622.0K | 66.0K | 410.0K |
| Inventory | 97.3M | 55.0M | 47.0M | 42.4M | 49.9M | 18.5M | 23.6M | 16.9M | 16.4M | 12.2M |
| Current assets | 281.1M | 242.1M | 128.3M | 183.5M | 141.8M | 200.9M | 148.1M | 109.9M | 64.4M | 51.5M |
| Property, plant and equipment | 163.8M | 167.6M | 165.7M | 163.8M | 163.2M | 159.8M | 161.6M | 156.3M | 155.7M | 95.4M |
| Goodwill | 245.0K | |||||||||
| Total assets | 524.2M | 465.7M | 344.7M | 405.1M | 369.8M | 435.0M | 388.8M | 305.7M | 262.4M | 237.4M |
| Accounts payable | 66.6M | 32.2M | 27.7M | 34.0M | 17.7M | 11.3M | 39.4M | 18.9M | 18.0M | 11.5M |
| Current liabilities | 126.2M | 88.9M | 84.2M | 92.5M | 78.7M | 66.3M | 60.8M | 41.3M | 43.3M | 19.7M |
| Long-term debt | 50.9M | 76.9M | 105.9M | 121.2M | 134.1M | 144.7M | 142.8M | 130.7M | 134.8M | 113.1M |
| Total debt | 96.6M | 121.4M | 153.6M | 172.3M | 184.1M | 188.3M | 155.6M | 147.3M | 155.0M | 117.2M |
| Total liabilities | 210.7M | 202.9M | 221.8M | 246.0M | 258.2M | 243.5M | 235.2M | 199.6M | 203.1M | 171.5M |
| Shareholders' equity | 313.5M | 262.8M | 122.9M | 159.1M | 111.6M | 191.5M | 153.6M | 106.1M | 59.3M | 65.9M |
| Shares outstanding | 129.4M | 122.2M | 83.2M | 73.7M | 70.1M | 63.2M | 50.4M | 44.0M | 34.6M | 32.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -111.9M | -91.8M | -74.8M | -63.0M | -93.8M | -96.9M | -77.6M | -44.1M | -54.4M | -38.3M |
| Capital spending | -26.6M | -19.2M | -6.22M | -5.44M | -7.44M | -4.63M | -7.35M | -909.0K | -5.81M | -63.2M |
| Free cash flow | -138.5M | -111.0M | -81.0M | -68.4M | -101.2M | -99.9M | -88.2M | -47.1M | -60.2M | -101.4M |
| Cash from investing | 22.4M | -38.0M | -2.86M | -6.16M | 61.5M | -6.84M | -20.5M | -27.3M | -2.16M | -21.7M |
| Cash from financing | 34.2M | 180.9M | 25.6M | 113.8M | 7.42M | 129.2M | 107.4M | 80.5M | 57.4M | 42.8M |
| Share buybacks | 57.5M | 217.0M | 45.0M | 128.3M | 0 | 107.3M | 100.0M | 89.3M | 27.6M | 27.6M |
| Change in cash | -55.3M | 51.6M | -49.9M | 44.6M | -26.0M | 27.3M | 9.09M | 12.4M | 797.0K | -17.2M |
Cap table
Built by 6ix from Biomm SA’s releases
- Common shares
- 136,852,484
- Fully diluted
- 136,852,484
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 136,852,484 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 136,852,484 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexandre Bernardes Gonçalves | Commercial Director · Since at least Nov 5, 2026 |
| André Capistrano Emrich | Member of the Executive Committee · Since at least Nov 5, 2026 |
| Anna Emilia Sousa Leite Gaetani | Manager · Since at least Nov 5, 2026 |
| Cláudio Luiz Lottenberg | Chairman of the Board · Since at least Nov 5, 2026 |
| Davi Khattar | Manager · Since at least Nov 5, 2026 |
| Francisco Carlos Marques de Freitas | Chief Technology Officer · Since at least Nov 5, 2026 |
| Guilherme Maradei | Chief Executive Officer · Since at least Nov 24, 2025 |
| Marclo Sáfadi Alvares | Chief Financial and Investor Relations Officer · Since at least Nov 5, 2026 |
| Walfrido Silvino dos Mares Guia Neto | Vice Chairman of the Board · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Biomm SA.